Search Results
Oct 01, 2025, 13:33 ET Mark Farrah Associates Assessed Second Quarter Health Insurance Membership Trends
from 2Q24. The Employer-group risk and Employer-group ASO segments provide the largest sources of coverage in the industry, however, while Employer-group ASO saw an enrollment increase of 1.2%, the Employer-group risk market experienced year-over-year membership
More news about: Mark Farrah Associates (MFA)
Sep 22, 2025, 11:16 ET RNA-based Therapies Market to Reach USD 213.54 Billion by 2033, Driven by Rare Diseases, Oncology, and Advances in RNA Technologies | DataM Intelligence
between Japanese firms and global biopharma for RNAi and ASO therapies.PMDA's regulatory flexibility, supporting clinical trials for RNA-based therapies targeting rare and genetic diseases.In 2025, NS Pharma advanced multiple ASO-based therapies into late-stage trials, reinforcing
More news about: DataM Intelligence 4 Market Research LLP
Sep 21, 2025, 20:29 ET AusperBio Raises $63 Million in Series B2 Financing to Accelerate Functional Cure Therapies for Chronic Hepatitis B
Med-OligoTM ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining efficient targeted delivery conjugation technologies, the modular Med-OligoTM Platform empowers ASO therapeutics to treat
More news about: AusperBio Therapeutics Inc.
Sep 18, 2025, 20:33 ET AusperBio Completes Enrollment in Two Phase II Clinical Trials of AHB-137 for Chronic Hepatitis B
proprietary Med-Oligo™ ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining with efficient targeted delivery conjugation technologies, the modular Med-Oligo™ Platform empowers ASO therapeutics to treat a
More news about: AusperBio Therapeutics Inc.